Gapping up
In reaction to strong earnings/guidance:
- NTNX +20.7%, DKS +12.9%, BBY +4.2%, DY +3.8%, AMBA +3.7%, CRH +2%, BURL +1.8%, PVH +1.4%, ARWR +1%, MOMO +0.9%, AMWD +0.9%, ANF +0.6%
Other news:
- CCXI +336.7% (co and Vifor Fresenius Medical announced "positive" top-line data from Phase III ADVOCATE trial of avacopan)
- KIN +19.9% (received FDA approval of Zimeta for control of equine pyrexia)
- SAFE +6.7% (appointed to join the S&P SmallCap 600)
- ARDX +5.8% (expands partnership with Kyowa Kirin with new agreements; receives $20 mln equity investment)
- EVFM +4.3% (resubmits New Drug Application to FDA for Amphora)
- GNFT +3.1% (announces that the Data Safety Monitoring Board issued positive recommendation for the continuation, without any modifications, of the RESOLVE-IT Phase 3 trial evaluating elafibranor in NASH)
- BCRX +1.5% (continued strength on light volume)
- CBAY +1.5% (after closing Monday's session down by 76%)
- AIG +1.2% (to sell majority interest in Fortitude Re for approx. $1.8 bln)
Analyst comments:
- CMG +1.7% (upgraded to Outperform from Market Perform at Cowen)
- DOC +1.3% (upgraded to Buy from Hold at Stifel)
- CERN +1.3% (initiated with a Buy at UBS)
- DIS +1.2% (initiated with an Overweight at Consumer Edge Research